Menactra: a meningococcal conjugate vaccine.
Menactra is the first conjugated meningococcal vaccine approved in the US. It protects against meningococcal serogroups A, C, Y and W-135. The CDC's Advisory Committee on Immunization Practices (ACIP) recommends administration of the new vaccine to pre-adolescents aged 11 or 12, teens entering high school and college freshmen living in dormitories. These broad recommendations have led to a shortage of the new vaccine. Menomune, the old unconjugated quadrivalent meningococcal vaccine, is also effective in these age groups and could still be used.
D000293:Adolescent; D000328:Adult; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D005252:Fees, Pharmaceutical; D006801:Humans; D022401:Meningococcal Vaccines / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*
D022401:Meningococcal Vaccines